Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Zenas BioPharma, Inc. Common Stock

ZBIO

Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies.

Last trade $27.82
Day change -$0.11 (-0.39%)
Day range $27.08 – $28.24
Volume 203,061
Market cap $1.89B

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$1.89B
Price / earnings
—
Price / book
7.67×
Price / sales
1,894.15×
EV / sales
1,994.59×
EV / EBITDA
-4.19×

Profitability

Earnings per share
-$7.14
Return on assets
-69.03%
Return on equity
-196.03%
Dividend yield
0%

Liquidity and leverage

Debt / equity
1.2×
Current ratio
9.93×
Quick ratio
9.93×
Cash ratio
2.99×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$225.97M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for ZBIO, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$1M$0$0$0$0$10M$5M$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$1M$0$0$0$0$10M$5M$0
Selling, general and administrative$15.75M$16.91M$15.59M$13.18M$12.14M$12.42M$11.47M$7.45M
Research and development$92.91M$60.44M$222.39M$39.4M$43.03M$34.92M$49.16M$33.53M
Total operating expenses$108.66M$77.35M$237.98M$52.58M$55.16M$47.33M$60.62M$40.98M
Operating income-$107.66M-$77.35M-$237.98M-$52.58M-$55.16M-$37.33M-$55.62M-$40.98M
Interest expense-$8.56M-$368K-$7.33M$0$0$0$0$0
Income before taxes-$111.34M-$80.99M-$240.34M-$51.5M-$52.2M-$33.78M-$52.18M-$38.61M
Income taxes$114K$0$106K$0$20K-$205K$429K$0
Net income-$111.46M-$80.99M-$240.44M-$51.5M-$52.22M-$33.57M-$52.6M-$38.61M
Net income attributable to common shareholders-$111.46M-$80.99M-$240.44M-$51.5M-$52.22M-$33.57M-$52.6M-$38.61M
EBITDA-$107.66M-$77.34M-$237.97M-$52.57M-$55.15M-$37.31M-$55.59M-$40.95M
Basic earnings per share-$1.77-$1.46-$4.53-$1.22-$1.25-$0.80-$1.25-$5.02
Diluted earnings per share-$1.77-$1.46-$4.53-$1.22-$1.25-$0.80-$1.25-$5.02

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
Zacks Investment Research

Wall Street Analysts Predict a 77.61% Upside in Zenas BioPharma, Inc. (ZBIO): Here's What You Should Know

Zenas BioPharma (ZBIO) has gained 2.7% over the past four weeks and closed at $28.23. Wall Street analysts have set a mean price target of $50.14, indicating a potential 77.6% upside. The stock holds a Zacks Rank #2 (Buy) rating, supported by positive earnings estimate revisions. However, the article cautions that price targets alone should not be the sole basis for investment decisions, as analysts often set overly optimistic targets due to business incentives.

GlobeNewswire Inc.

Zenas BioPharma Announces the Presentation of New Obexelimab Data in IgG4-Related Disease at the 6th International Symposium on IgG4-Related Disease

Zenas BioPharma presented new clinical data for obexelimab at the 6th International Symposium on IgG4-Related Disease. Phase 3 INDIGO open-label extension results showed sustained clinical activity with a 93% probability of remaining flare-free at 12 months, significantly reduced glucocorticoid toxicity compared to placebo, and positive vaccine responses during a treatment-free window. The data supports obexelimab's potential as a steroid-sparing B-cell inhibitor for long-term IgG4-RD management.

GlobeNewswire Inc.

Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Zenas BioPharma announced on September 15, 2026, that its Compensation Committee granted inducement stock options to purchase 53,700 shares and 98,900 restricted stock units to newly hired employees. The stock options have a 10-year term with an exercise price of $31.93 per share and vest over four years, while RSUs vest equally over four years through 2030.

GlobeNewswire Inc.

Zenas BioPharma Announces Data from the Registrational Phase 3 INDIGO Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD), Simultaneously Presented at the EULAR 2026 Congress and Published in the New England Journal of Medicine

Zenas BioPharma announced that obexelimab met its primary and all key secondary endpoints in the Phase 3 INDIGO trial for Immunoglobulin G4-Related Disease (IgG4-RD). The drug demonstrated a 56% reduction in flare risk, 65% reduction in glucocorticoid use, and favorable safety profile comparable to placebo. A Biologics License Application (BLA) was submitted to the FDA in May 2026, with results presented at EULAR 2026 Congress and published in the New England Journal of Medicine.

GlobeNewswire Inc.

Zenas BioPharma Reports First Quarter 2026 Financial Results and Provides Corporate Update

Zenas BioPharma reported Q1 2026 financial results with cash position of $718.5M and extended runway through Q2 2029. The company advanced obexelimab toward FDA/EMA submissions for IgG4-RD treatment, completed enrollment in the Phase 2 SunStone SLE trial with results expected Q4 2026, initiated Phase 1 testing of oral IL-17 inhibitor ZB021, and continued Phase 3 trials for orelabrutinib in multiple sclerosis. R&D expenses increased to $60.4M from $34.9M year-over-year, and net loss widened to $81.0M from $33.6M, primarily due to increased clinical trial and manufacturing costs.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

Ex-dividendAmount / sharePay dateType
Dec 24, 2019$0.002Jan 2, 2020recurring
Sep 25, 2019$0.0171Oct 2, 2019recurring
Jun 25, 2019$0.0155Jul 2, 2019recurring
Mar 20, 2019$0.0133Mar 27, 2019recurring
Dec 26, 2018$0.005Jan 3, 2019recurring

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
May 24, 20181-for-2reverse split